SCHEMBL21366239

SCHEMBL21366239

COC(=O)c1csc(Cc2c[nH]c3ccccc23)n1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.63
MEN1 O00255 3/20 0.63
KMT2A Q03164 3/20 0.63
GPR84 Q9NQS5 7/20 0.57
AHR P35869 2/20 0.50
NR1I2 O75469 1/20 0.50
SRC P12931 1/20 0.50
HDAC1 Q13547 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
CYP3A4 P08684 2/20 0.49
CYP1A2 P05177 1/20 0.49
POLB P06746 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
NR4A2 P43354 1/20 0.49
CREBBP Q92793 1/20 0.49
TDP1 Q9NUW8 2/20 0.47
LMNA P02545 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13848490 0.88 PKM (0.54) MAPTMEN1KMT2AGPR84AHR
SCHEMBL21366214 0.82 MAPT (0.70) MAPTMEN1KMT2AGPR84AHR
SCHEMBL21366219 0.81 MEN1 (0.65) MAPTMEN1KMT2AGPR84AHR
SCHEMBL21448958 0.79 MAPT (0.66) MAPTMEN1KMT2AGPR84AHR
SCHEMBL21448917 0.78 MAPT (0.65) MAPTMEN1KMT2AGPR84AHR
SCHEMBL21448959 0.78 MAPT (0.65) MAPTMEN1KMT2AGPR84AHR
SCHEMBL21366220 0.78 MAPT (0.65) MAPTMEN1KMT2AGPR84AHR
SCHEMBL21448916 0.78 MEN1 (0.65) MAPTMEN1KMT2AGPR84AHR
SCHEMBL23551150 0.78 GPR84 (0.54) MAPTMEN1KMT2AGPR84AHR
SCHEMBL29567209 0.77 MEN1 (1.00) MAPTMEN1KMT2AGPR84AHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3564239-B9 ARYL HYDROCARBON RECEPTOR MODULATOR ARIAGEN INC (US) 2023-04-19 EP disclosed
US-20230054194-A1 Methods of Treating Cancer ARIAGEN, INC. (US) 2023-02-23 US disclosed
US-11547698-B2 Aryl hydrocarbon receptor modulators ARIAGEN, INC. (US) 2023-01-10 US disclosed
US-11459322-B2 Indole compounds and their use ARIAGEN, INC. (US) 2022-10-04 US disclosed
US-20210179604-A1 Indole Compounds and Their Use ARIAGEN, INC. (US) 2021-06-17 US disclosed
US-20200354353-A1 Indole Compounds and Their Use ARIAGEN, INC. (US) 2020-11-12 US disclosed
EP-3564239-A1 ARYL HYDROCARBON RECEPTOR MODULATOR Shenzhen Immunova Pharmaceutical Co., Ltd. (CN) 2019-11-06 EP disclosed
US-20190330201-A1 ARYL HYDROCARBON RECEPTOR MODULATORS AHR PHARMACEUTICALS, INC. 2019-10-31 US disclosed
US-20190307731-A1 ARYL HYDROCARBON RECEPTOR MODULATOR ARIAGEN, INC. (US) 2019-10-10 US disclosed
US-20190284149-A1 ARYL HYDROCARBON RECEPTOR MODULATOR ARIAGEN, INC. (US) 2019-09-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190307731-A1 ARYL HYDROCARBON RECEPTOR MODULATOR AHR, ARNT, NR1H4 MAPT 4875/4885MEN1 4131/4885KMT2A 1490/4885
US-11547698-B2 Aryl hydrocarbon receptor modulators AHR, ARNT, CNR1 MAPT 4838/4885MEN1 4176/4885KMT2A 1471/4885
US-20210179604-A1 Indole Compounds and Their Use IDO1, IDO2, INMT MAPT 2556/4885MEN1 2883/4885KMT2A 1124/4885
US-11459322-B2 Indole compounds and their use IDO1, IDO2, INMT MAPT 2556/4885MEN1 2883/4885KMT2A 1124/4885
US-20200354353-A1 Indole Compounds and Their Use IDO1, IDO2, INMT MAPT 2556/4885MEN1 2883/4885KMT2A 1124/4885
US-20190284149-A1 ARYL HYDROCARBON RECEPTOR MODULATOR AHR, ARNT, NR1H4 MAPT 4863/4885MEN1 4131/4885KMT2A 1445/4885
US-20190330201-A1 ARYL HYDROCARBON RECEPTOR MODULATORS AHR, ARNT, CNR1 MAPT 4838/4885MEN1 4176/4885KMT2A 1471/4885
US-20230054194-A1 Methods of Treating Cancer TP53, MSH2, PDCD1 MAPT 3515/4885MEN1 1911/4885KMT2A 1118/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.